Author:
Meille Christophe,Barbolosi Dominique,Ciccolini Joseph,Freyer Gilles,Iliadis Athanassios
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference46 articles.
1. Morales S, Lorenzo A, Ramos M, Ballesteros P, Mendez M, Almanza C, et al. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemother Pharmacol. 2004;53(1):75–81.
2. Nishimura R, Rai Y, Matsuo F, Anan K, Hara S, Imamura S, et al. Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial. Anticancer Res. 2012;32(8):3259–65.
3. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–9.
4. Cottu PH, Extra JM, Espie M, Marolleau JP, DeRoquancourt A, Makke J, et al. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. Br J Cancer. 2001;85(9):1240–6.
5. Friedrichs K, Holzel F, Janicke F. Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. Eur J Cancer. 2002;38(13):1730–8.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献